Langdon et al. used two PI3K/mTOR inhibitors, gedatolisib and PF-04691502, to study six human patient-derived ovarian cancer xenograft models and found that both compounds exhibit antitumour activity on all the experimental substances, and the initial tumour volume inhibitory effect seems to be the strongest. This evidence concerns the gene MTOR and neoplasm.